Johnson & Johnson - New heart technology Javelin impresses with 93.6% success!
Reading Time: 3 minutes
At the TCT conference, Shockwave Javelin achieved a 93.6% technical success rate in 158 patients. Javelin is designed to reach narrow passages that conventional balloon catheters can hardly pass. Shockwave is already growing by 17%. The new catheter reduces the pressure wave treatment time by half. Johnson & Johnson (JNJ) presented new data on Shockwave Javelin at the TCT 2026 Cardiologist Congress on November 1. The catheter could expand the business for calcified coronary arteries. On October 30, the stock reached a 52-week high of...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
